IP Library › Granted Patent US 12,528,810
Granted Patent B2
US 12,528,810 · App. 16/586,536 · Granted Jan 20, 2026

Small molecule inhibitors of DYRK/CLK and uses thereof

Inventors: Christopher Hulme (Tucson, AZ); Christopher Foley (Tucson, AZ)
Assignee: Arizona Board of Regents on Behalf of the University of Arizona
C07D487/04C07D401/14C07D403/14C07D413/14C07D417/14C07D471/04C07D498/08C07D498/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,528,810
App. No.
16/586,536
Granted
Jan 20, 2026
Kind
B2
Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Claims (46)

1 . A compound having any one of the following formulas:

including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof;

wherein R1 is selected from hydrogen,

wherein R, R′, and R7 are independently selected from hydrogen, fluorine, bromine, chlorine, iodine, di-fluorine, di-bromine, di-chlorine, di-iodine, CF3, OCH3, CHF2H, OCF3, methyl, di-methyl, alkoxy, alkylsulfonyl, cyano, carboxy, ester, amido, substituted amido, sulfonamide, substituted sulfonamide, methylenedioxy, heterocyclyl alkyl, heterocyclyl, heterocyclyl alkyl amido, a lipophilic moiety comprising ether functionality, methyl, ethyl, (CH 2 ) 3 ,

wherein X′, Y′, Z′ are independently N, C or CO;

wherein R8 is selected from hydrogen, C1-C4 alkyl, heterocyclyl alkyl, heteroaryl alkyl, aryl alkyl, aryl, heterocyclyl, and heteroaryl;

wherein R2 is selected from hydrogen, fluorine, aryl, heteroaryl, substituted heteroaryl,

 (wherein Bn is benzyl or heterobenzyl),

 (wherein X″ is selected from alkyl, haloalkyl, amino, alkylamino, hydroxy, fluoro, chloro, bromo, cyano groups);

wherein R3 is selected from hydrogen, fluorine, aryl, substituted aryl, heteroaryl, substituted heteroaryl,

 (wherein Bn is benzyl or heterobenzyl),

 (wherein X″ is selected from alkyl, haloalkyl, amino, alkylamino, hydroxy, fluoro, chloro, bromo, cyano groups);

wherein R4 is selected from hydrogen, CH 3 , NH 2 , CN,

 and

wherein R5 is selected from hydrogen, fluorine, methyl, and methoxy; and

wherein R6 is present and is selected from hydrogen, fluorine, methyl, and methoxy,

wherein if the compound is encompassed within

 then

1) R1, R2, R3, R4 and R5 cannot all be hydrogen;

2) if R2 is

 then R1 cannot be

3) if R2, R3, R4 and R5 are hydrogen, then R1 cannot be

4) R1 cannot be any of the following:

5) if R2 is

 then R1, R3, R4 and R5 cannot be hydrogen; and

6) if R2 is

 then R1, R3, R4 and R5 cannot be hydrogen.

2 . The compound of claim 1 , wherein the compound is capable of inhibiting DYRK1A protein.

3 . The compound of claim 1 , wherein the compound is capable of binding a DYRK1A protein at the Lys188 position of the DYRK1A protein.

4 . A method for inhibiting DYRK1A related activity in a subject, comprising administering to the subject a compound of claim 1 .

5 . The method of claim 4 , wherein administration of the compound results in inhibition of one or more DYRK1A related activities in the subject selected from the group consisting of:

DYRK1A related PI3K/Akt signaling;

DYRK1A related tau phosphorylation;

DYRK1A related NFAT phosphorylation;

DYRK1A related ASK1/JNK1 pathway activation;

DYRK1A related p53 phosphorylation;

DYRK1A related Amph 1 phosphorylation;

DYRK1A related Dynamin 1 phosphorylation;

DYRK1A related Synaptojanin phosphorylation;

DYRK1A related presenilin 1 (the catalytic sub-unit of γ-secretase) activity;

DYRK1A related Amyloid precursor protein phosphorylation; and

DYRK1A related SIRT1 activation.

6 . The method of claim 4 , wherein administration of the compound results in binding of the compound with DYRK1A at the Lys188 position of the DYRK1A protein.

7 . The method of claim 4 , wherein the subject is human subject suffering from or at risk for developing a disorder related to DYRK1A activity.

8 . The method of claim 7 , wherein the disorder related to DYRK1A activity is Alzheimer's disease, Down syndrome, Huntington's disease, Parkinson's disease, autoimmune disease, an inflammatory disorder, or cancer.

9 . The compound of claim 1 , wherein the compound is selected from any of the compounds provided in the following table:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2020
From: HULME, CHRISTOPHER; FOLEY, CHRISTOPHER
To: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Reel/Frame 052125/0206 →
Continuity (3)
Continuation In Part 15756917 · Sep 28, 2018
Provisional Application 62738540 · Mar 1, 2018
Related Publication 20200039989A1 · Feb 6, 2020
References Cited (110)
US 3989816A · Rajadhyaksha · 1976 [cited by applicant]
US 4331671A · Lesher et al. · 1982 [cited by applicant]
US 4444762A · Rajadhyaksha · 1984 [cited by applicant]
US 4569934A · Moran · 1986 [cited by examiner]
US 6218388B1 · Boschelli et al. · 2001 [cited by applicant]
US 7238713B2 · Anderson et al. · 2007 [cited by applicant]
US 7666879B2 · Barda et al. · 2010 [cited by applicant]
US 20020019415A1 · Camden · 2002 [cited by applicant]
US 20050026960A1 · Kephart et al. · 2005 [cited by applicant]
US 20110112091A1 · Brzozka et al. · 2011 [cited by applicant]
US 20140080831A1 · Roux · 2014 [cited by examiner]
US 20150203472A1 · Ceccarelli et al. · 2015 [cited by applicant]
US 20160326178A1 · Zhuo et al. · 2016 [cited by applicant]
US 20180208600A1 · Nacro et al. · 2018 [cited by applicant]
CN 104447567 · 2015 [cited by applicant]
DE 102014009011 · 2014 [cited by applicant]
JP 57136583 · 1982 [cited by applicant]
WO WO9916755 · 1999 [cited by applicant]
WO WO2005009997 · 2005 [cited by applicant]
WO WO2005092866 · 2005 [cited by applicant]
WO WO2008045371 · 2008 [cited by applicant]
WO WO2010007317 · 2010 [cited by applicant]
WO WO2010080503 · 2010 [cited by applicant]
WO WO2011022439 · 2011 [cited by applicant]
WO WO2012174312 · 2012 [cited by applicant]
WO WO2013026806 · 2013 [cited by applicant]
WO WO2013147711 · 2013 [cited by applicant]
WO WO2014053409 · 2014 [cited by applicant]
WO WO2014096388 · 2014 [cited by applicant]
WO WO2014151147 · 2014 [cited by applicant]
WO 2017040993 · 2017 [cited by applicant]
WO WO2017044623A1 · 2017 [cited by examiner]
WO WO2017055530 · 2017 [cited by applicant]
WO WO2017055533 · 2017 [cited by applicant]
Chesterfield et al. Journal of the Chemical Society, 1960, Issue 0, pp. 4590-4596. [cited by examiner]
Le Manach et al. Journal of Med. Chemistry, Published Oct. 14, 2014, vol. 57, pp. 8839-8848. [cited by examiner]
Wamg. L-L. Acta Crystallographica, Section 8, 2007, vol. 63, No. 4., Abstract. [cited by examiner]
Le Manach et al. ((2014), Medicinal Chemistry Optimization of Antiplasmodial Imidazopyridazine Hits from High Throughput Screening of a SoftFocus Kinase Library: Part 2, J. Med. Chem., 2014, 57, 8839-8848 (Year: 2014). [cited by examiner]
Le Manach et al. ((2014), Medicinal Chemistry Optimization of Antiplasmodial Imidazopyridazine Hits from High Throughput Screening of a SoftFocus Kinase Library: Part 2, J. Med. Chem., 57, 8839-8848) (Year: 2014). [cited by examiner]
Ali et al. (2014) Input of Isosteric and Bioisosteric Approach in Drug Design, J. Chem. Soc. Pak., 36, p. 150-169. (Year: 2014). [cited by examiner]
International Search Report & Written Opinion, Int'l Application No. PCT/US2019/053620, mailed Feb. 3, 2020, 12 pages. [cited by applicant]
Humphries et al. 8-Fluoroimidazo[1,2-a]pyridine: Synthesis, physicochemical properties and evaluation as a pioisosteric . . . Bioorganic & Medicinal Chemistry Letters, 16 (2006) Jan. 4, 2006, pp. 1518-1522. [cited by applicant]
Ahn et al., Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol. Jul. 2005;12(7):811-23. [cited by applicant]
Ahn et al., DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol Dis. Jun. 2006;22(3):463-72. [cited by applicant]
Airaksinen et al., Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines. Pharmacol Toxicol. Jan. 1987;60(1):5-8. [cited by applicant]
Albores et al., Mitochondrial respiratory inhibition by N-methylated Beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine, PNAS 1990;87:9368-9372. [cited by applicant]
Altafaj et al., Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice . . . , Hum Mol Genet 2001;10:1915-1923. [cited by applicant]
Anderson et al., Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors., Bioorg. Med. Chem. Lett., 2013, 23(24), 6610-6615. [cited by applicant]
Arron et al., NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature. Jun. 1, 2006;441(7093):595-600. [cited by applicant]
Bain et al., The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315. [cited by applicant]
Bain et al., The specificities of protein kinase inhibitors: an update., Biochem J 2003;371:199-204. [cited by applicant]
Becker et al., Activation, regulation, and inhibition of DYRK1A. Febs J. Jan. 2011;278(2):246-56. [cited by applicant]
Belichenko et al., Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J Comp Neurol. Oct. 1, 2007;504(4):329-45. [cited by applicant]
Belichenko et al., The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci. May 6, 2009;29(18):5… [cited by applicant]
Belinchenko et al., Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol. Dec. 13, 2004;480(3):281-98. [cited by applicant]
Bojjireddy et al., Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J… [cited by applicant]
Branca et al., Dyrk1 inhibition improves Alzheimer's disease-like pathology. Aging Cell. Oct. 2017;16(5):1146-1154. [cited by applicant]
Branchi et al., Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J Neuropathol Exp… [cited by applicant]
Bullock et al., Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure. Mar. 11, 2009;17(3):352-62. [cited by applicant]
Callaway et al., Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol 1999;65:243-256. [cited by applicant]
Chabert et al., Functional analysis of genes implicated in Down syndrome: 1. Cognitive abilities in mice transpolygenic for Down Syndrome Chromosomal Region-1 (DCR-1). Behav Genet. Nov. 2004;34(6):559-69. [cited by applicant]
Chen et al., Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Mol Cell. Oct. 10, 2013;52(1):87-100. [cited by applicant]
Cohen. Protein kinases—the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1(4), 309-315. [cited by applicant]
Coombs et al., Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315, Bioorg Med Chem Lett 2013, 23, 3654… [cited by applicant]
De La Torre et al., Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res 2014;58:278-288. [cited by applicant]
Deng et al., Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells, Genes & Cancer (2014), 5(9-10), 337-347. [cited by applicant]
Druillennec et al., Alternative splicing in oncogenic kinases: from physiological functions to cancer. J Nucleic Acids. 2012;2012:639062. 14 pages. [cited by applicant]
Examination Report, Australian Patent Application No. 2016315881, mailed May 26, 2019, 7 pages. [cited by applicant]
Extended European Search Report for PCT/US2019/053620. Mailed Jun. 9, 2022. 8 pages. [cited by applicant]
Farahat et al., Copper(I) 3-Methylsalicylate Mediates the Chan-Lam N-Arylation of Heterocycles. Synthetic Communications, 2015, vol. 45(2), pp. 245-252. [cited by applicant]
Fedorov et al., Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. Jan. 28, 2011;18(1):67-76. [cited by applicant]
Frost et al., β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites, PLoS One 2011;6:e19264. [cited by applicant]
Fuentes et al., An investigation on the central effects of harmine, harmaline and related beta-carbolines. Neuropharmacology 1971;10:15-23. [cited by applicant]
Gambelunghe et al., Identification of N,N-dimethyltryptamine and β-carbolines in psychotropic ayahuasca beverage, Biomed Chromatogr 2008;22:1056-1059. [cited by applicant]
Guo et al., DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem. Apr. 23, 2010;285(17):13223-32. [cited by applicant]
Hamann et al., Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure-Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer's Disease J. Nat. Prod., 2007, 70(9), 1397-1405. [cited by applicant]
Hämmerle et al., Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development. Jun. 2011;138(12):2543-… [cited by applicant]
Hitchcock, Structure-Brain Exposure Relationships J. Med. Chem., 2006, 49(26), 7559-83. [cited by applicant]
International Search Reoprt and Written Opinion, International Patent Application No. PCT/US2016/050198, mailed Feb. 7, 2017. [cited by applicant]
Ionescu et al., DYRK1A kinase inhibitors with emphasis on cancer. Mini Rev Med Chem. Nov. 2012;12(13):1315-29. 15 pages. [cited by applicant]
Jain et al., Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr Drug Targets. May 2014;15(5):539-50. 12 pages. [cited by applicant]
Kawanishi et al., Relationship between occurrence of tremor/convulsion and level of beta-carbolines in the brain after administration of beta-carbolines into mice. Pharmacol Biochem Behav. Mar. 1994;47(3):689-99. [cited by applicant]
Khor et al., The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife. May 22, 2015;4:e05920. 27 pages. [cited by applicant]
Liu et al., Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener. Jul. 10, 2008;3:8. 10 pages. [cited by applicant]
Lott et al., Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet neurology 2010;9:623-633. [cited by applicant]
Megarbane et al., The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med 2009;11:611-616. [cited by applicant]
Mennenga et al., Harmine treatment enhances short-term memory in old rats: Dissociation of cognition and the ability to perform the procedural requirements of maze testing. Physiol Behav. Jan. 2015;138:260-5. 16 pages. [cited by applicant]
Michan et al., SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. Jul. 21, 2010;30(29):9695-707. [cited by applicant]
Nemoto et al., Constitutive activity of glycogen synthase kinase-3β: Positive regulation of steady-state levels of insulin receptor substrates-1 and -2 in adrenal chromaffin cells Brain Research 2006, 1110(1), 1-12. [cited by applicant]
Neumann et al., DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. Feb. 12, 2018;8(1):2859. pp. 1-12. [cited by applicant]
Oumata et al., Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J. Med. Chem., 2008, 51(17), 5229-5242. [cited by applicant]
Pagano et al., Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. Dec. 2, 2004;47(25):6239-47. [cited by applicant]
Palmer et al., Structure-Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor. J. Med. Chem. 1998, 41, 27, 5457-5465. [cited by applicant]
Perez et al., Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med. Res. Rev., 2011, 31(6), 924-954. [cited by applicant]
Reeves et al., A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 1995;11:177-184. [cited by applicant]
Roskoski. USFDA approved protein kinase inhibitors. Blue Ridge Institute for Medical Research. Horse Shoe, NC. 2017, 13 pages www.brimr.org/PKI/PKIs.htm. [cited by applicant]
Ryoo et al., Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neuroc… [cited by applicant]
Ryoo et al., DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 2007;282:34850-34857. [cited by applicant]
Sago et al., Ts1Cje, a partial trisomy 16 mouse model for Down syndrome exhibits learning and behavioral abnormalities. PNAS 1998;95:6256-6261. [cited by applicant]
Seifert et al., DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. FEBS J. Dec. 2008;275(24):6268-80. [cited by applicant]
Siarey et al., Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 2005;49:122-128. [cited by applicant]
Smith et al., Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet 1997;16:28-36. [cited by applicant]
Smith et al., Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem Neurosci. Nov. 21, 2012;3(11):857… [cited by applicant]
Tahtouh et al., Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B. J Med Chem 2012, 55, 9312-9… [cited by applicant]
Tamminana et al., Preparation of 2-Azido-1-Substituted-1H-Benzo[d]imidazoles Using a Copper-Promoted Three-Component Reaction and Their Further Conversion into 2-Amino and 2-Triazolyl Derivatives. Chemistry—A European J… [cited by applicant]
Velazquez et al., Chronic Dyrk1 Inhimition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. Molecular Neurobiology. 2019. 1-12. [cited by applicant]
Wang et al., Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res. Jul. 15, 2008;68(14):5628-38. 26 pages. [cited by applicant]
Zheng et al., A palladium-catalyzed regiospecific synthesis of N-aryl benzimidazoles. Angew Chem Int Ed Engl. 2007;46(39):7509-12. [cited by applicant]
Zhong et al., A QSAR study on inhibitory activities of 1-phenylbenzimidazoles against the platelet-derived growth factor receptor. Bioorganic & Medicinal Chemistry. 2004. 12. 4009-4015. [cited by applicant]
Ziegler et al., A Versatile Approach to Ullmann C—N Couplings at Room Temperature: New Families of Nucleophiles and Electrophiles for Photoinduced, Copper-Catalyzed Processes. J. Am. Chem. Soc. 2013, 135, 35, 13107-1311… [cited by applicant]